These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34499685)

  • 1. Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis.
    Boettiger DC; Chattranukulchai P; Avihingsanon A; Chaiwarith R; Khusuwan S; Law MG; Ross J; Kiertiburanakul S
    PLoS One; 2021; 16(9):e0256926. PubMed ID: 34499685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
    Boettiger DC; Newall AT; Chattranukulchai P; Chaiwarith R; Khusuwan S; Avihingsanon A; Phillips A; Bendavid E; Law MG; Kahn JG; Ross J; Bautista-Arredondo S; Kiertiburanakul S
    J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25494. PubMed ID: 32562359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States.
    Boettiger DC; Newall AT; Phillips A; Bendavid E; Law MG; Ryom L; Reiss P; Mocroft A; Bonnet F; Weber R; El-Sadr W; d'Arminio Monforte A; de Wit S; Pradier C; Hatleberg CI; Lundgren J; Sabin C; Kahn JG; Kazi DS
    J Int AIDS Soc; 2021 Mar; 24(3):e25690. PubMed ID: 33749164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease.
    Wang M; Liu J; Bellows BK; Qi Y; Sun J; Liu J; Moran AE; Zhao D
    Glob Heart; 2020 Jun; 15(1):43. PubMed ID: 32923337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Jarmul J; Pletcher MJ; Hassmiller Lich K; Wheeler SB; Weinberger M; Avery CL; Jonas DE; Earnshaw S; Pignone M
    Circ Cardiovasc Qual Outcomes; 2018 Apr; 11(4):e004171. PubMed ID: 29650716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease.
    Jiang Y; Ni W
    Pharmacoeconomics; 2019 Jul; 37(7):943-952. PubMed ID: 30875022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.
    Desai NR; Campbell C; Electricwala B; Petrou M; Trueman D; Woodcock F; Cristino J
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):545-556. PubMed ID: 35595929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in statin prescription among veterans with HIV and known atherosclerotic cardiovascular disease.
    Erqou S; Papaila A; Halladay C; Ge A; Liu MA; Jiang L; Lally M; Menon A; Shah NR; Miech E; Virani SS; Zullo AR; Shireman TI; Longenecker CT; Ross D; Sullivan JL; Wu WC; Rudolph JL
    Am Heart J; 2022 Jul; 249():12-22. PubMed ID: 35318028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective.
    Xie W; Song Y; Qin X; Jin P
    Adv Ther; 2023 Feb; 40(2):489-503. PubMed ID: 36371480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
    Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
    Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underprescribing of statin therapy in people with HIV at risk for atherosclerotic cardiovascular disease.
    Gallegos Aragon K; Ray G; Conklin J; Stever E; Marquez C; Magallanes A; Anderson J; Jakeman B
    Am J Health Syst Pharm; 2022 Nov; 79(22):2026-2031. PubMed ID: 35976174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
    Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
    J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.
    Fonarow GC; van Hout B; Villa G; Arellano J; Lindgren P
    JAMA Cardiol; 2019 Jul; 4(7):691-695. PubMed ID: 31166576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing rates of statin therapy in eligible patients living with HIV versus uninfected patients.
    Blackman AL; Pandit NS; Pincus KJ
    HIV Med; 2020 Mar; 21(3):135-141. PubMed ID: 31876122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
    Ademi Z; Ofori-Asenso R; Zomer E; Owen A; Liew D
    Eur J Prev Cardiol; 2021 Jul; 28(8):897-904. PubMed ID: 34298556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes.
    Li T; Wan X; Ma J; Wu B
    Adv Ther; 2018 Dec; 35(12):2214-2223. PubMed ID: 30390239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of statin therapy among people living with HIV.
    Boettiger DC; Kerr S; Chattranukulchai P; Siwamogsatham S; Avihingsanon A
    AIDS; 2021 Mar; 35(4):567-574. PubMed ID: 33252492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.